|
US5866A
(en)
|
|
1848-10-17 |
|
Dentist s deill |
|
US69A
(en)
|
|
1836-10-27 |
|
Machine eor picking or breaking wool and ginned or seedless cotton |
|
US6649A
(en)
|
|
1849-08-14 |
|
Arrangement of steam-boiler |
|
US6927A
(en)
|
|
1849-12-04 |
|
Improvement in pumps for raising water |
|
US366A
(en)
|
|
1837-08-31 |
|
Quadrant hinge foe |
|
US138A
(en)
|
|
1837-03-08 |
|
Barnabas s |
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4888278A
(en)
|
1985-10-22 |
1989-12-19 |
University Of Massachusetts Medical Center |
In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
|
|
US5447841A
(en)
|
1986-01-16 |
1995-09-05 |
The Regents Of The Univ. Of California |
Methods for chromosome-specific staining
|
|
US6280929B1
(en)
|
1986-01-16 |
2001-08-28 |
The Regents Of The University Of California |
Method of detecting genetic translocations identified with chromosomal abnormalities
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4774339A
(en)
|
1987-08-10 |
1988-09-27 |
Molecular Probes, Inc. |
Chemically reactive dipyrrometheneboron difluoride dyes
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
AU634186B2
(en)
|
1988-11-11 |
1993-02-18 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5132432A
(en)
|
1989-09-22 |
1992-07-21 |
Molecular Probes, Inc. |
Chemically reactive pyrenyloxy sulfonic acid dyes
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5274113A
(en)
|
1991-11-01 |
1993-12-28 |
Molecular Probes, Inc. |
Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
|
|
US5433896A
(en)
|
1994-05-20 |
1995-07-18 |
Molecular Probes, Inc. |
Dibenzopyrrometheneboron difluoride dyes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5248782A
(en)
|
1990-12-18 |
1993-09-28 |
Molecular Probes, Inc. |
Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
|
|
US5338854A
(en)
|
1991-02-13 |
1994-08-16 |
Molecular Probes, Inc. |
Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes
|
|
US5427932A
(en)
|
1991-04-09 |
1995-06-27 |
Reagents Of The University Of California |
Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
|
|
US5187288A
(en)
|
1991-05-22 |
1993-02-16 |
Molecular Probes, Inc. |
Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
US5262357A
(en)
|
1991-11-22 |
1993-11-16 |
The Regents Of The University Of California |
Low temperature thin films formed from nanocrystal precursors
|
|
US5505928A
(en)
|
1991-11-22 |
1996-04-09 |
The Regents Of University Of California |
Preparation of III-V semiconductor nanocrystals
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
DK1589107T3
(da)
|
1992-08-21 |
2010-04-26 |
Univ Bruxelles |
Immonuglobuliner uden lette kæder
|
|
US6048616A
(en)
|
1993-04-21 |
2000-04-11 |
Philips Electronics N.A. Corp. |
Encapsulated quantum sized doped semiconductor particles and method of manufacturing same
|
|
US5472842A
(en)
|
1993-10-06 |
1995-12-05 |
The Regents Of The University Of California |
Detection of amplified or deleted chromosomal regions
|
|
EP0690452A3
(en)
|
1994-06-28 |
1999-01-07 |
Advanced Micro Devices, Inc. |
Electrically erasable memory and method of erasure
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
US5571018A
(en)
|
1994-11-23 |
1996-11-05 |
Motorola, Inc. |
Arrangement for simulating indirect fire in combat training
|
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5690807A
(en)
|
1995-08-03 |
1997-11-25 |
Massachusetts Institute Of Technology |
Method for producing semiconductor particles
|
|
US6207157B1
(en)
|
1996-04-23 |
2001-03-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Conjugate vaccine for nontypeable Haemophilus influenzae
|
|
US5800996A
(en)
|
1996-05-03 |
1998-09-01 |
The Perkin Elmer Corporation |
Energy transfer dyes with enchanced fluorescence
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
US5830912A
(en)
|
1996-11-15 |
1998-11-03 |
Molecular Probes, Inc. |
Derivatives of 6,8-difluoro-7-hydroxycoumarin
|
|
US5696157A
(en)
|
1996-11-15 |
1997-12-09 |
Molecular Probes, Inc. |
Sulfonated derivatives of 7-aminocoumarin
|
|
US5866366A
(en)
|
1997-07-01 |
1999-02-02 |
Smithkline Beecham Corporation |
gidB
|
|
US6130101A
(en)
|
1997-09-23 |
2000-10-10 |
Molecular Probes, Inc. |
Sulfonated xanthene derivatives
|
|
US6322901B1
(en)
|
1997-11-13 |
2001-11-27 |
Massachusetts Institute Of Technology |
Highly luminescent color-selective nano-crystalline materials
|
|
US6207392B1
(en)
|
1997-11-25 |
2001-03-27 |
The Regents Of The University Of California |
Semiconductor nanocrystal probes for biological applications and process for making and using such probes
|
|
US5990479A
(en)
|
1997-11-25 |
1999-11-23 |
Regents Of The University Of California |
Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6566131B1
(en)
|
2000-10-04 |
2003-05-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Smad6 expression
|
|
US6617583B1
(en)
|
1998-09-18 |
2003-09-09 |
Massachusetts Institute Of Technology |
Inventory control
|
|
US6410323B1
(en)
|
1999-08-31 |
2002-06-25 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of human Rho family gene expression
|
|
US6114038A
(en)
|
1998-11-10 |
2000-09-05 |
Biocrystal Ltd. |
Functionalized nanocrystals and their use in detection systems
|
|
US6855202B2
(en)
|
2001-11-30 |
2005-02-15 |
The Regents Of The University Of California |
Shaped nanocrystal particles and methods for making the same
|
|
US6107091A
(en)
|
1998-12-03 |
2000-08-22 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of G-alpha-16 expression
|
|
US5981732A
(en)
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
US6046321A
(en)
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
|
ATE439452T1
(de)
|
1999-05-07 |
2009-08-15 |
Life Technologies Corp |
Verfahren zum nachweis von analyten mit hilfe von halbleiternanokrystallen
|
|
US7838222B2
(en)
|
1999-07-26 |
2010-11-23 |
United States of America/ NIH |
Methods, devices and kits for multiplex blotting of biological samples from multi-well plates
|
|
US6969615B2
(en)
|
1999-07-26 |
2005-11-29 |
20/20 Genesystems, Inc. |
Methods, devices, arrays and kits for detecting and analyzing biomolecules
|
|
US7214477B1
(en)
|
1999-07-26 |
2007-05-08 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Layered device with capture regions for cellular analysis
|
|
ES2269171T3
(es)
|
1999-07-26 |
2007-04-01 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal |
Dispositivo en capas con regiones de captura para analisis celular.
|
|
ES2282133T3
(es)
|
1999-08-24 |
2007-10-16 |
Medarex, Inc. |
Anticuerpos frente a la ctla-4 humano y sus usos.
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US6225198B1
(en)
|
2000-02-04 |
2001-05-01 |
The Regents Of The University Of California |
Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process
|
|
US6306736B1
(en)
|
2000-02-04 |
2001-10-23 |
The Regents Of The University Of California |
Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process
|
|
EP1276904B1
(en)
|
2000-03-22 |
2013-08-28 |
Life Technologies Corporation |
Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
|
|
AU2001275078A1
(en)
|
2000-06-01 |
2001-12-11 |
The Board Of Regents For Oklahoma State University |
Bioconjugates of nanoparticles as radiopharmaceuticals
|
|
US6365354B1
(en)
|
2000-07-31 |
2002-04-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of lysophospholipase I expression
|
|
AU2001279185B2
(en)
|
2000-08-04 |
2005-07-07 |
Molecular Probes, Inc. |
Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings
|
|
US6942970B2
(en)
|
2000-09-14 |
2005-09-13 |
Zymed Laboratories, Inc. |
Identifying subjects suitable for topoisomerase II inhibitor treatment
|
|
US6566135B1
(en)
|
2000-10-04 |
2003-05-20 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of caspase 6 expression
|
|
US6649138B2
(en)
|
2000-10-13 |
2003-11-18 |
Quantum Dot Corporation |
Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
|
|
US20020083888A1
(en)
|
2000-12-28 |
2002-07-04 |
Zehnder Donald A. |
Flow synthesis of quantum dot nanocrystals
|
|
US6670113B2
(en)
|
2001-03-30 |
2003-12-30 |
Nanoprobes |
Enzymatic deposition and alteration of metals
|
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
|
US6709929B2
(en)
|
2001-06-25 |
2004-03-23 |
North Carolina State University |
Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates
|
|
US20060073141A1
(en)
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
US6815064B2
(en)
|
2001-07-20 |
2004-11-09 |
Quantum Dot Corporation |
Luminescent nanoparticles and methods for their preparation
|
|
JP4488740B2
(ja)
|
2001-11-13 |
2010-06-23 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
免疫細胞活性化を調節する作用剤およびその使用方法
|
|
ATE395413T1
(de)
|
2001-12-03 |
2008-05-15 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
|
AU2003288675B2
(en)
|
2002-12-23 |
2010-07-22 |
Medimmune Limited |
Antibodies against PD-1 and uses therefor
|
|
GB0229734D0
(en)
|
2002-12-23 |
2003-01-29 |
Qinetiq Ltd |
Grading oestrogen and progesterone receptors expression
|
|
US7257268B2
(en)
|
2003-02-28 |
2007-08-14 |
Aperio Technologies, Inc. |
Systems and methods for image pattern recognition
|
|
WO2004080579A2
(en)
|
2003-03-10 |
2004-09-23 |
Expression Pathology, Inc. |
Liquid tissue preparation from histopatologically processed biological samples, tissues and cells
|
|
US7642064B2
(en)
|
2003-06-24 |
2010-01-05 |
Ventana Medical Systems, Inc. |
Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
|
|
DE602004022165D1
(de)
|
2003-06-24 |
2009-09-03 |
Ventana Med Syst Inc |
Enzymkatalysierte metalldeposition zum verstärkten und nukleinsäuresequenzen
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
JP2008541015A
(ja)
|
2005-04-28 |
2008-11-20 |
ベンタナ・メデイカル・システムズ・インコーポレーテツド |
ナノ粒子コンジュゲート
|
|
EP3144675A1
(en)
|
2005-04-28 |
2017-03-22 |
Ventana Medical Systems, Inc. |
Enzymes conjugated to antibodies via a peg heterobifuctional linker
|
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
|
UA96139C2
(ru)
*
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитело к нейропилину-1 (nrp1)
|
|
US20070117153A1
(en)
|
2005-11-23 |
2007-05-24 |
Christopher Bieniarz |
Molecular conjugate
|
|
ATE525482T1
(de)
|
2005-12-23 |
2011-10-15 |
Nanostring Technologies Inc |
Nanoreporter und verfahren zu deren herstellung und verwendung
|
|
US8986926B2
(en)
|
2005-12-23 |
2015-03-24 |
Nanostring Technologies, Inc. |
Compositions comprising oriented, immobilized macromolecules and methods for their preparation
|
|
US7629125B2
(en)
|
2006-11-16 |
2009-12-08 |
General Electric Company |
Sequential analysis of biological samples
|
|
US7741045B2
(en)
|
2006-11-16 |
2010-06-22 |
General Electric Company |
Sequential analysis of biological samples
|
|
NZ614857A
(en)
|
2007-03-29 |
2015-04-24 |
Genmab As |
Bispecific antibodies and methods for production thereof
|
|
US8415102B2
(en)
|
2007-04-10 |
2013-04-09 |
Nanostring Technologies, Inc. |
Methods and computer systems for identifying target-specific sequences for use in nanoreporters
|
|
US8023714B2
(en)
|
2007-06-06 |
2011-09-20 |
Aperio Technologies, Inc. |
System and method for assessing image interpretability in anatomic pathology
|
|
DK2170959T3
(da)
|
2007-06-18 |
2014-01-13 |
Merck Sharp & Dohme |
Antistoffer mod human programmeret dødsreceptor pd-1
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
ES2684317T3
(es)
|
2008-08-14 |
2018-10-02 |
Nanostring Technologies, Inc |
Nanoinformadores estables
|
|
WO2010033508A1
(en)
|
2008-09-16 |
2010-03-25 |
Historx, Inc. |
Reproducible quantification of biomarker expression
|
|
CN102264762B
(zh)
|
2008-09-26 |
2018-03-27 |
达纳-法伯癌症研究公司 |
人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
|
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
|
|
AU2010204741B2
(en)
|
2009-01-14 |
2016-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ratio based biomarkers and methods of use thereof
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
|
US20110111435A1
(en)
|
2009-11-06 |
2011-05-12 |
SlidePath Limited |
Detecting Cell Surface Markers
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
US20130022629A1
(en)
|
2010-01-04 |
2013-01-24 |
Sharpe Arlene H |
Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
|
|
BR112012026766B1
(pt)
|
2010-04-20 |
2021-11-03 |
Genmab A/S |
Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
|
|
PL2581113T3
(pl)
|
2010-06-11 |
2018-11-30 |
Kyowa Hakko Kirin Co., Ltd. |
Przeciwciało anty-tim-3
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012168944A1
(en)
|
2011-06-08 |
2012-12-13 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
EP2822957A1
(en)
|
2012-03-07 |
2015-01-14 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
RU2014143443A
(ru)
|
2012-03-29 |
2016-05-20 |
Ориджин Дискавери Текнолоджиз Лимитед |
Иммуномодулирующие циклические соединения
|
|
PE20150336A1
(es)
|
2012-05-25 |
2015-03-25 |
Univ California |
Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
|
|
CA2886120A1
(en)
*
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
|
ES2786193T3
(es)
|
2012-12-12 |
2020-10-09 |
Broad Inst Inc |
Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
EP3252160B1
(en)
|
2012-12-12 |
2020-10-28 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
DK2970155T3
(en)
|
2013-03-15 |
2018-08-06 |
Bristol Myers Squibb Co |
INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
|
|
HUP1300432A2
(hu)
|
2013-07-10 |
2015-01-28 |
Tamas Kardos |
Downhill kerékpár szerkezet javított felfüggesztéssel
|
|
CA2922607C
(en)
|
2013-09-06 |
2022-08-30 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole derivatives as immunomodulators
|
|
EP3041828B1
(en)
|
2013-09-06 |
2018-05-23 |
Aurigene Discovery Technologies Limited |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
WO2015048577A2
(en)
|
2013-09-27 |
2015-04-02 |
Editas Medicine, Inc. |
Crispr-related methods and compositions
|
|
CN107074947B
(zh)
|
2014-08-05 |
2021-04-09 |
马布奎斯特公司 |
结合至pd-1的免疫试剂
|
|
EP3356411B1
(en)
*
|
2015-10-02 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specific for pd1 and tim3
|
|
WO2017075451A1
(en)
*
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
EA201990978A1
(ru)
*
|
2016-11-08 |
2019-12-30 |
Актиджен Лтд |
Антитела против pd-1
|
|
JOP20190134A1
(ar)
*
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
|
WO2018213260A1
(en)
*
|
2017-05-16 |
2018-11-22 |
Immunogen, Inc. |
Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations
|
|
CA3060989A1
(en)
*
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
US20230042913A1
(en)
*
|
2017-06-05 |
2023-02-09 |
The Council Of The Queensland Institute Of Medical Research |
A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
|
|
EP3887399A1
(en)
*
|
2018-11-30 |
2021-10-06 |
Institut Gustave-Roussy |
Anti-neuropilin-1 and anti-programmed cell death-1 combination therapy for treating cancer
|